Cost regulators for NHS funded therapies in England and Wales have now published final draft guidance approving GlaxoSmithKline’s gene therapy Strimvelis for an ultra-rare immune deficiency condition commonly referred to as bubble baby syndrome. More: NICE publishes final draft guidelines
read moreFive months after blocking the products of Prosana Distribuciones from the U.S., the FDA has issued a warning letter for the Mexican company. More: FDA slaps Mexico’s Prosana with warning letter after finding it faked records Source: fierce
read moreIf you thought 2017 was a game-changer for immuno-oncology, just wait. In the first half of 2018 alone, each of the four major players—Merck, Bristol-Myers Squibb, Roche and AstraZeneca—is expecting a phase 3 data readout that Bernstein analyst Tim Anderson
read moreLast year was tough for drugmakers, as investors shunned Big Pharma companies facing new competition for their blockbusters and insurers loudly protested pricing of newer products. More of the same is ahead, analysts figure, but some companies are better able
read moreA New Year often rings in higher drug prices, and many top drugmakers marked the occasion in just that way this year. But none of the increases topped the 10% price-hike cap that’s been trendy in pharma since 2016. More:
read moreFollowing two weeks of strikes, Teva workers in Israel have won a small victory through their efforts to save manufacturing jobs. Meanwhile, new CEO Kåre Schultz has gotten a lesson in the difficulties of making cuts in the company’s home
read more© 1994 - 2026 B.M. Pharmaceuticals